Pharmacodynamics, pharmacokinetics and tissue distribution of liposomal mitoxantrone hydrochloride

Yaoxue Xuebao

Volumn 45, Issue 12, 2010, Pages 1565-1569

  Wang, Cai Xia ^a,b   Li, Chun Lei ^a,b   Zhao, Xi ^a,b   Yang, Han Yu ^a,b   Wei, Na ^a,b   Li, Yan Hui ^a,b   Zhang, Li ^a,b   Zhang, Lan ^a,b  

^a Hebei Pharmaceutical Engineering and Technology Research Center   (China)

^b CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co   (China)

Author keywords

Liposome; Mitoxantrone; Pharmacodynamics; Pharmacokinetics; Tissue distribution

Indexed keywords

MITOXANTRONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; DOG; DRUG MECHANISM; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; SINGLE DRUG DOSE; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CELL LINE, TUMOR; CELL PROLIFERATION; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOXANTRONE; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; SARCOMA 180; TISSUE DISTRIBUTION;

EID: 78650649652     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Koeller J, EbIe M. Mitoxantrone: a novel anthracycline derivative [J]. Clin Pharm, 1988, 7: 574-581.
2. Wiseman LR, Spencer CM. Mitoxantrone: a review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer [J]. Drugs Aging, 1997, 10:473-485.
3. Dunn CJ, Goa KL. Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia [J]. Drugs Aging, 1996, 9: 122-147.
4. Kroger N, Damon L, Zander AR, et al. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients [J]. Bone Marrow Transplant, 2003, 32: 1153-1157.
5. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies [J]. Clin Pharmacokinet, 2003, 42: 419-436.
6. Immordino ML, Dosio F, Cartel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential [J]. Int J Nanomed, 2006, 1: 297-315.
7. Johnson JL, Ahmad A, Khan S, et al. Improved liquid chromatographic method for mitoxantrone quantification in mouse plasma and tissues to study the pharmacokinetics of a liposome entrapped mitoxantrone formulation [J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2004, 799: 149-155.
8. Lim HJ, Masin D, Madden TD, et al. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone [J]. J Pharmacol Exp Ther, 1997, 281: 566-573.
9. Li CL, Cui JX, Wang CX, et al. Lipid composition and grafted PEG affect in vivo activity of liposomal mitoxantrone [J]. Int J Pharm, 2008, 362: 60-66.
10. Li CL, Cui JX, Wang CX, et al. Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy [J]. Eur J Pharm Biopharm, 2008,70: 665-668.
11. Cui JX, Li CL, Guo WM, et al. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy? [J]. J Control Release, 2007,118:204-215.